{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-11T22:04:58.506Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-11. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-11. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-11, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"GUTS\",\n  \"company\": \"Fractyl Health, Inc.\",\n  \"investigation_summary\": \"Fractyl Health is a clinical-stage metabolic biotech (obesity/T2D) with two programs: Revita DMR (endoscopic duodenal mucosal resurfacing for post-GLP-1 weight maintenance) and Rejuva gene therapy (pancreatic GLP-1 expression). The investigation was triggered by 6 Form 4 filings in the last 14 days. Of these, TWO are genuine open-market P/S buys: Director William Bradley purchased 68,493 shares at $0.7348 on June 10 ($50,329) and CFO Lara Smith Weber purchased 20,000 shares at $0.6854 on June 8 ($13,708). The remaining four filings from directors on June 10 were stock option grants (A code), not purchases — noise for the thesis. The stock trades at ~$0.72, down ~70% from its 52-week high of $2.37 following a catastrophic January 2026 dilution event and poor mid-cohort REMAIN-1 data. Near-term catalysts include REVEAL-1 one-year open-label readout (June 4, 2026 — strong: 78% weight loss retention at one year), Q3 2026 REMAIN-1 Midpoint Cohort topline, early Q4 2026 REMAIN-1 Pivotal Cohort six-month data, and a potential late-Q4 2026 FDA De Novo submission. Cash runway extends into early 2027 per management, but the company flagged going-concern risk in its 10-Q.\",\n  \"verdict\": \"promising\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"long_stock\"\n  ],\n  \"business_snapshot\": \"Fractyl Health is a clinical-stage metabolic therapeutics company with two distinct platforms targeting obesity and type 2 diabetes. The primary near-term value driver is Revita DMR, an outpatient endoscopic hydrothermal ablation procedure designed to remodel the duodenal lining to enable durable weight maintenance after GLP-1 drug discontinuation — a high-value unmet need given >50% GLP-1 dropout within three months. Revita has FDA Breakthrough Device Designation and favorable De Novo feedback; pivotal data readout is early Q4 2026 with submission expected late Q4 2026. The Rejuva platform (gene therapy for local pancreatic GLP-1 expression) just received Netherlands CTA authorization in April 2026 and expects first-in-human dosing H2 2026, adding optionality. Financially, the company is pre-revenue with heavy R&D burn; it reported a Q1 2026 non-GAAP profit of $9.2M but this was driven entirely by warrant liability remeasurement gains — not operational. Cash of $63.2M vs. debt of $60.8M; runway into early 2027 per management. Key risks include going-concern disclosure, massive dilution history (IPO + two follow-on offerings in 2025), and a January 2026 stock collapse from ~$1.83 to $0.46 following disappointing REMAIN-1 data.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"William Bradley\",\n          \"role\": \"Director\",\n          \"amount_usd\": 50329,\n          \"date\": \"2026-06-10\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526267851/xslF345X06/ownership.xml\"\n        },\n        {\n          \"insider\": \"Lara Smith Weber\",\n          \"role\": \"CFO\",\n          \"amount_usd\": 13708,\n          \"date\": \"2026-06-08\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526264430/xslF345X06/ownership.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 64037,\n      \"distinct_insider_buyers_90d\": 2,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": true,\n      \"material_insider_selling_90d_usd\": 0,\n      \"notable_13f_holders\": [\n        \"pending — v2\"\n      ],\n      \"politician_recent_buys\": [\n        \"pending — v2\"\n      ]\n    },\n    \"catalyst\": {\n      \"next_earnings_date\": \"2026-08-11\",\n      \"recent_eps_surprise_pattern\": \"Q4 2025 beat by +61%; Q3 2025 miss of -125% (largely one-time items); Q1 2026 reported non-GAAP net income driven by warrant remeasurement, not operations\",\n      \"guidance_raise_in_last_90d\": false,\n      \"named_catalysts\": [\n        {\n          \"type\": \"clinical_data\",\n          \"description\": \"REVEAL-1 Cohort one-year open-label data: patients retained ~78% of GLP-1-induced weight loss at one year post-Revita; 33% continued losing weight. Zero serious procedure-related AEs.\",\n          \"date_or_window\": \"June 4, 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526256445/guts-20260604.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"clinical_data\",\n          \"description\": \"REMAIN-1 Midpoint Cohort one-year randomized data readout expected Q3 2026; pivotal six-month topline data expected early Q4 2026\",\n          \"date_or_window\": \"Q3–Q4 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526219373/guts-20260331.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"regulatory\",\n          \"description\": \"FDA De Novo marketing application submission anticipated in late Q4 2026 for Revita post-GLP-1 weight maintenance indication\",\n          \"date_or_window\": \"Late Q4 2026\",\n          \"source_urls\": [\n            \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526121793/guts-20251231.htm\"\n          ],\n          \"directional_bias\": \"bullish\"\n        },\n        {\n          \"type\": \"clinical_data\",\n          \"description\": \"RJVA-001 first-in-human Phase 1/2 dosing expected H2 2026 in Netherlands (CTA authorized April 2026); preliminary data expected H2 2026\",\n          \"date_or_window\": \"H2 2026\",\n          \"source_urls\": [\n            \"https://finance.yahoo.com/sectors/healthcare/articles/fractyl-health-authorized-initiate-first-110000649.html\"\n          ],\n          \"directional_bias\": \"bullish\"\n        }\n      ]\n    },\n    \"mispricing\": {\n      \"forward_pe\": null,\n      \"sector_median_forward_pe\": null,\n      \"ev_to_ebitda\": -1.24,\n      \"sector_median_ev_to_ebitda\": null,\n      \"fcf_yield_pct\": null,\n      \"sotp_gap_pct\": null,\n      \"narrative\": \"GUTS trades at $0.72 with a ~$115M market cap and analyst consensus target of $5.24 (7x current price). The stock collapsed from $2.37 to $0.46 in January 2026 on disappointing REMAIN-1 data, then partially recovered on positive catalysts in Q2 2026 (+93% in one month per May news). Despite strong REVEAL-1 one-year results and CTA authorization for RJVA-001, the stock remains deeply discounted relative to the analyst $5.24 mean price target — suggesting market has not fully priced the upcoming pivotal data readout (early Q4 2026) or a potential De Novo approval pathway.\"\n    },\n    \"quality\": {\n      \"roic_pct\": null,\n      \"gross_margin_trend_pp_yoy\": null,\n      \"net_debt_to_ebitda\": null,\n      \"balance_sheet_grade\": \"C\"\n    },\n    \"technical\": {\n      \"above_50dma\": true,\n      \"above_200dma\": false,\n      \"rsi_14\": 46.8,\n      \"macd_recent_bullish_cross\": false,\n      \"12_1_momentum_vs_sector_pct\": null\n    }\n  },\n  \"price_context\": {\n    \"last_close\": 0.7239,\n    \"ytd_return_pct\": -53.89,\n    \"from_52w_high_pct\": -70.4\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-03-24\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526121793/guts-20251231.htm\",\n      \"key_takeaways\": [\n        \"FY 2025 net loss; going-concern disclosure confirmed; $63.2M cash vs $60.8M debt; multiple equity offerings in 2025 (August and September ATM) caused massive dilution; Revita De Novo feedback favorable; REMAIN-1 pivotal fully randomized February 2026 with topline expected early Q4 2026\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-12\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526219373/guts-20260331.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 net income of $9.2M driven by warrant liability remeasurement ($30.1M gain); operating loss of $(20.8M); cash burn accelerating; RJVA-001 CTA authorized Netherlands April 2026; CFO open-market buy June 8, 2026 (20K shares at $0.6854); Nasdaq minimum bid price notice received March 13 — has until September 9, 2026 to regain compliance\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-06-04\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526256445/guts-20260604.htm\",\n      \"key_takeaways\": [\n        \"REVEAL-1 one-year data: ~78% weight loss retention at one year; 33% continued losing weight; zero serious procedure-related AEs; 100% maintained ≥5% of GLP-1-induced weight loss through one year — strong clinical validation for Revita\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [],\n    \"iv_summary\": \"No options expiries returned by the tool. GUTS appears to have minimal listed options market activity — this limits structured income strategies significantly.\",\n    \"notable_skew_or_flow\": \"Minimal liquid options market; no notable UOA data available.\"\n  },\n  \"competitive_landscape\": \"Fractyl competes in a landscape dominated by GLP-1 agonists (Novo Nordisk's semaglutide, Eli Lilly's tirzepatide). Revita's differentiation is procedural/disease-modifying weight maintenance — addressing the key gap of >50% GLP-1 discontinuation within three months. Direct competitors for post-GLP-1 management are minimal. Rejuva gene therapy competes in a broader T2D/obesity gene therapy space (early stage, largely preclinical).\",\n  \"key_risks\": [\n    \"Going-concern disclosure in 10-Q despite Q1 'profit' — warrant remeasurement gain is non-cash and non-recurring; massive dilution history with three equity offerings in 2025 alone causing severe shareholder dilution; stock collapsed ~75% from 52-week high to January 2026 low on REMAIN-1 disappointment, suggesting market skepticism of clinical thesis; cash runway only into early 2027 will require additional capital raise before pivotal data readout — potential shareholder-unfriendly event; Nasdaq minimum bid price compliance risk (must stay above $1.00 by September 9, 2026); RJVA-001 is still Phase 1/2 in Netherlands with significant clinical execution risk; Revita De Novo pathway has regulatory uncertainty despite favorable FDA feedback\"\n  ],\n  \"what_the_market_might_be_missing\": \"The most underappreciated signal: CFO open-market purchase of $13,708 on June 8 at $0.6854 — a non-routine buy for a CFO who was just appointed January 2026 and previously served as Controller at the company. This suggests insider conviction beyond routine director compensation. The REVEAL-1 one-year data (June 4) showing 78% weight retention is a strong clinical signal that Revita's mechanism works, yet the stock only trades at $0.72 vs analyst target of $5.24. The gap between current price and consensus suggests market has not priced in the full probability-weighted value of an early Q4 pivotal readout. The January crash to $0.46 on a single data disappointment created an asymmetric entry — if pivotal data hits, the re-rating from ~$0.72 toward analyst targets ($2-$8) represents 3-11x upside.\",\n  \"anti_signals_present\": [\n    \"going_concern\",\n    \"dilution\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"10-K FY2025 (filed March 24, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526121793/guts-20251231.htm\"\n    },\n    {\n      \"label\": \"10-Q Q1 2026 (filed May 12, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526219373/guts-20260331.htm\"\n    },\n    {\n      \"label\": \"8-K REVEAL-1 results (June 4, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526256445/guts-20260604.htm\"\n    },\n    {\n      \"label\": \"Form 4 — Bradley open-market purchase June 10, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526267851/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Form 4 — Smith Weber CFO open-market purchase June 8, 2026\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1572616/000119312526264430/xslF345X06/ownership.xml\"\n    },\n    {\n      \"label\": \"Q1 2026 earnings + RJVA-001 CTA authorization news (May 12 and May 11, 2026)\",\n      \"url\": \"https://finance.yahoo.com/news/fractyl-health-reports-first-quarter-200500915.html\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-11T22:05:57.570Z",
      "raw_content": "<think>The dossier is for Fractyl Health, Inc. (GUTS).\nLet's evaluate against the scoring rubric and risk gates.\n\nRisk Class: Market cap is ~$115M. This is ≤ $5B, so \"asymmetric\" risk class.\nAnti-Signals:\n- \"going_concern\" is present in anti_signals_present.\n- \"dilution\" is present.\nThe prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nGoing-concern disclosure means high risk of bankruptcy/dilution. Dilution is explicitly flagged. This is a clinical-stage biotech with $63.2M cash vs accelerating burn, runway into early 2027, and Nasdaq compliance risk.\nThis strongly points to SKIP.\n\nLet's score it anyway to be thorough, but the anti-signal gate for going-concern is a hard skip unless I can articulate why it doesn't apply. Here, it clearly applies. The company has a going-concern qualification, accelerating cash burn, and needs to raise capital before the Q4 2026 pivotal data. This creates massive dilution risk that outweighs the clinical catalyst upside.\nAlso, the prompt says: \"Paper-tracking lane... Do not paper-track dossiers with methodology anti-signals, stale numbers, missing sources, unverified catalyst dates, or generic 'cheap/AI/tailwind' stories. Skip those.\"\nSo it must be skipped.\n\nLet's calculate the score to justify the skip:\nA. Smart Money: 2 insiders bought ($64k total). Not ≥ $500K. CEO buy absent. CFO buy present (+3). Total < $5M. No politician/13F. Score: 3/25.\nB. Options Flow: No options data. Score: 0/10.\nC. Catalyst: REVEAL-1 data June 4 (past date, but strong). REMAIN-1 Q3/Q4. De Novo late Q4. No earnings within 90 days with >0% surprise pattern. Score: 8 (pending product/clinical milestone) or maybe 5 (guidance raise absent). Let's give 8/25.\nD. Mispricing: Pre-revenue, negative EV/EBITDA, no FCF. Score: 0/15.\nE. Quality: Pre-revenue, negative earnings. Score: 0/15.\nF. Technical: Above 50DMA, below 200DMA. RSI 46.8. Score: 3/10.\nTotal Score: ~14/100.\n\nAnti-signal: going_concern, dilution.\nVerdict: Skip.\nReason: The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution/bankruptcy risk that overrides the clinical catalyst upside. As an asymmetric small-cap biotech with no earnings, negative margins, and a hard anti-signal gate, it fails the publish threshold.\n\nI will output the skip JSON.\nCheck constraints:\n- Output ONLY valid JSON.\n- Follow skip format exactly.\n- Score breakdown matches rubric.\n- Reason 1-2 sentences.\n\nAll good.\nProceed. \nLet's double check the anti-signal rule: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will articulate that it does apply and is fatal.\nScore breakdown:\nsmart_money: 3\noptions_flow: 0\ncatalyst: 8\nmispricing: 0\nquality: 0\ntechnical: 3\nTotal: 14.\nMatches.\nOutput matches format.\nReady. \nOne minor point: The prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". Selling is 0, so no penalty.\nScore is low anyway.\nI will generate the JSON. \nStructure of output:\n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 3,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\"\n}\nCheck date rules: No dates in output except maybe in reason, but I'll keep it generic or use 2027 as given in dossier. All good.\nProceeds. \nOutput matches exactly.✅\nNote: I'll make sure the JSON is perfectly formatted.\nDone. \nSelf-Correction/Refinement during thought: \nWait, the prompt says \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nI will just state that the anti-signal applies and is fatal. That's standard.\nScore is 14.\nAll good.\nOutput matches request. \nProceeds. \n[Output Generation] -> JSON only. \n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 3,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\"\n}\nMatches perfectly. No extra text. Valid JSON. Dates checked. Rubric applied. Anti-signal handled. Risk class noted implicitly by low score. All constraints met.\nDone. \nOutput Generation. \n(Self-Correction/Verification during drafting)\nWait, let's verify the score breakdown math: 3+0+8+0+0+3 = 14. Correct.\nCheck rubric caps: smart_money max 25, options max 10, catalyst max 25, mispricing max 15, quality max 15, technical max 10. All within caps.\nCheck anti-signal rule: \"going_concern\" is explicitly in anti_signals_present. I will note it applies.\nCheck date rule: No future dates needed in skip output.\nAll good.\nProceeds. \nOutput matches exactly. \n[Done] \n`{ \"skip\": true, \"score\": 14, \"score_breakdown\": { \"smart_money\": 3, \"options_flow\": 0, \"catalyst\": 8, \"mispricing\": 0, \"quality\": 0, \"technical\": 3 }, \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\" }`\nReady. \nOutput Generation. \n(Note: I will format it nicely as valid JSON without markdown fences as requested: \"OUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.\")\nDone. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 3,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 3,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 14,\n  \"score_breakdown\": {\n    \"smart_money\": 3,\n    \"options_flow\": 0,\n    \"catalyst\": 8,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 3\n  },\n  \"reason\": \"The dossier flags a going-concern disclosure and accelerating cash burn with runway only into early 2027, creating a severe dilution and bankruptcy risk that overrides the clinical catalyst upside. As a pre-revenue small-cap biotech with a hard anti-signal gate and no earnings or positive quality metrics, it fails the publish threshold.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 59065,
  "stop_reason": "stop",
  "completed_at": "2026-06-11T22:05:57.571Z"
}